Phaseline

Targets › EGF

EGF (Pro-epidermal growth factor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2028.

EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. (UniProt, P01133)

Open in Phaseline: the race on EGF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Henry Ford Health SystemuhCG/EGF
Combination of urinary-derived human chorionic gonadotropin and epidermal growth factor
EGFPhase 1Graft Versus Host DiseaseNov 2028

Conditions

Graft Versus Host Disease (1)

Modalities

small molecule (1)

Companies

Henry Ford Health System (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.